In another approach, based on the unique mechanism of action of LSD1 in intratumoral CD8+ T cells mediated by its interaction with TCF1 long isoform, we propose that antagonists, either small molecules or biologics that disrupt the interaction between LSD1 and the long isoform TCF1, could be developed in cancer checkpoint blockade therapy. The gene discussed is KDM1A; the disease is cancer.